Your browser doesn't support javascript.
loading
Patient-Derived Cancer Organoids for Precision Oncology Treatment.
Pernik, Mark N; Bird, Cylaina E; Traylor, Jeffrey I; Shi, Diana D; Richardson, Timothy E; McBrayer, Samuel K; Abdullah, Kalil G.
Afiliação
  • Pernik MN; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
  • Bird CE; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
  • Traylor JI; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
  • Shi DD; Department of Radiation Oncology, Harvard Medical School, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Richardson TE; Biggs Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
  • McBrayer SK; Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
  • Abdullah KG; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
J Pers Med ; 11(5)2021 May 17.
Article em En | MEDLINE | ID: mdl-34067714
ABSTRACT
The emergence of three-dimensional human organoids has opened the door for the development of patient-derived cancer organoid (PDO) models, which closely recapitulate parental tumor tissue. The mainstays of preclinical cancer modeling include in vitro cell lines and patient-derived xenografts, but these models lack the cellular heterogeneity seen in human tumors. Moreover, xenograft establishment is resource and time intensive, rendering these models difficult to use to inform clinical trials and decisions. PDOs, however, can be created efficiently and retain tumor-specific properties such as cellular heterogeneity, cell-cell and cell-stroma interactions, the tumor microenvironment, and therapeutic responsiveness. PDO models and drug-screening protocols have been described for several solid tumors and, more recently, for gliomas. Since PDOs can be developed in clinically relevant time frames and share many characteristics of parent tumors, they may enhance the ability to provide precision oncologic care for patients. This review explores the current literature on cancer organoids, highlighting the history of PDO development, organoid models of glioma, and potential clinical applications of PDOs.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article